Skip to content

US · GELS · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Gelteq Limited Ordinary Shares (GELS) intrinsic value and stock valuation

$0.27as of 2026-11-21 · Mkt cap 5.12M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Gelteq Limited Ordinary Shares DCF and intrinsic value

InvestorsCraft values GELS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GELS’s statements →

Healthcare · Drug Manufacturers - Specialty & Generic Clayton, VIC 3800 gelteq.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$170K
20202025
Net income
-$-6.65M
20202025
Free cash flow
-$-6.16M
20202025
Total equity
$15.8M+135.1% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$170K$0.00$80K$150K$0.00
Operating income-$-5.5M-$-2.95M-$-3.1M-$-3.19M-$-650K
Net income-$-6.65M-$-3.55M-$-3.51M-$-3.37M-$-650K
EPSd——-$-371.82K-$-356.99K-$-68.86K
Operating cash flow-$-5.52M-$-1.07M-$-1.77M$0.00$0.00
Capital expenditure-$-640K-$-150K-$-80K$0.00$0.00
Free cash flow-$-6.16M-$-1.22M-$-1.85M-$-1.51M-$-280K
Total assets$21.5M$20.8M$22.5M$23.4M$24.2M
Total debt$4.22M$3.84M$2.49M$1.51M$170K
Net debt$3.87M$3.82M$2.09M$1.35M-$-10K
Total equity$15.8M$15.1M$18.7M$20.9M$23.8M
Cash and short-term investments$340K$20K$400K$160K$180K
Income statement
20252024202320222021
Revenue$170K$0.00$80K$150K$0.00
Cost of revenue$0.00$0.00$50K$90K$0.00
Gross profit$170K$0.00$30K$50K$0.00
Research and development expenses$630K$280K$670K$530K$280K
Selling, general and administrative expenses$2.22M$1.27M$1.7M$1.55M$460K
Other expenses$2.81M$1.4M$770K$1.17M-$-90K
Operating expenses$5.66M$2.95M$3.13M$3.25M$650K
Cost and expenses$5.66M$2.95M$3.18M$3.34M$650K
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$1.89M$590K$400K$170K$0.00
Depreciation and amortization$1.22M$1.21M$1.23M$1.22M$60K
Ebitda-$-3.53M-$-1.75M-$-1.88M-$-1.98M-$-590K
Operating income-$-5.5M-$-2.95M-$-3.1M-$-3.19M-$-650K
Total other income/expenses, net-$-1.15M-$-600K-$-400K-$-180K-$0.00
Income before tax-$-6.65M-$-3.55M-$-3.51M-$-3.37M-$-650K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6.65M-$-3.55M-$-3.51M-$-3.37M-$-650K
Weighted average shares outstanding$0.00$0.00$9.44M$9.44M$9.44M
Weighted average diluted shares outstanding$0.00$0.00$9.44M$9.44M$9.44M
Balance sheet
20252024202320222021
Cash and short-term investments$340K$20K$400K$160K$180K
Net receivables$460K$180K$350K$250K$190K
Inventory$0.00$0.00$100K$100K$0.00
Total current assets$1.51M$300K$990K$720K$370K
Property, plant and equipment, net$20K$20K$10K$40K$0.00
Goodwill and intangible assets$19.9M$20.4M$21.5M$22.7M$23.8M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$20M$20.5M$21.5M$22.7M$23.8M
Total assets$21.5M$20.8M$22.5M$23.4M$24.2M
Accounts payable$180K$390K$290K$220K$90K
Short-term debt$4.2M$2.08M$20K$40K$0.00
Deferred revenue$0.00$130K$90K$120K$0.00
Total current liabilities$5.63M$3.87M$1.36M$1.08M$240K
Long-term debt$10K$1.76M$2.47M$1.47M$170K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$40K$1.78M$2.47M$1.47M$170K
Capital lease obligations$0.00$0.00$10K$50K$0.00
Total liabilities$5.67M$5.65M$3.84M$2.55M$400K
Common stock$34M$26.6M$26.6M$25.3M$24.9M
Retained earnings-$-18.14M-$-11.5M-$-7.95M-$-4.48M-$-1.11M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$30K$0.00
Total equity$15.8M$15.1M$18.7M$20.9M$23.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$4.22M$3.84M$2.49M$1.51M$170K
Net debt$3.87M$3.82M$2.09M$1.35M-$-10K
Cash flow statement
20252024202320222021
Net income$0.00-$-3.55M-$-3.51M$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$0.00$0.00$0.00$0.00$0.00
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-5.52M-$-1.07M-$-1.77M$0.00$0.00
Investments in property, plant and equipment-$0.00-$0.00-$-30K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$140K
Net cash used for investing activities-$-740K-$-150K-$-80K$0.00$140K
Common stock issued$7.91M$0.00$1.43M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.45M$840K$2.03M$1.49M$0.00
Net change in cash$320K-$-370K$240K-$-20K-$-140K
Cash at end of period$340K$20K$400K$160K$180K
Operating cash flow-$-5.52M-$-1.07M-$-1.77M$0.00$0.00
Capital expenditure-$-640K-$-150K-$-80K$0.00$0.00
Free cash flow-$-6.16M-$-1.22M-$-1.85M-$-1.51M-$-280K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Gelteq Limited Ordinary Shares

        Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.

        CEO
        Nathan Jacob Givoni
        Employees
        18
        Beta
        -0.43

        Explore

        Frequently asked questions

        What is the intrinsic value of Gelteq Limited Ordinary Shares (GELS)?

        InvestorsCraft does not currently publish an intrinsic value for GELS. How the IC value is calculated.

        Is GELS undervalued?

        InvestorsCraft does not publish an undervaluation signal for GELS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.